Navigation Links
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
Date:11/20/2007

Summary: Genmab and GSK Have Announced the Initiation of the Phase III

Program With Ofatumumab to Treat Rheumatoid Arthritis.

COPENHAGEN, Denmark, November 20 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) and GlaxoSmithKline (LSE and NYSE: GSK) announced today the initiation of the Phase III program with ofatumumab to treat rheumatoid arthritis (RA). The program will commence with two studies (GEN410/OFA110635 and GEN411/OFA110634) which will be conducted outside the US, in two distinct patient populations. One study will be in patients who have had an inadequate response to methotrexate therapy and the other in patients who had an inadequate response to TNF-alpha antagonist therapy. Further studies to support the program are planned for 2008.

Each study will evaluate the efficacy of ofatumumab in reducing the clinical signs and symptoms in RA patients after a single course of ofatumumab and are comprised of a 24 week double-blind period followed by a 120 week open-label period during which re-treatment will be studied. The primary endpoint in each study is ACR20 at 24 weeks.

"This brings us closer to our goal of broadening the treatment options for patients with this painful and debilitating disease," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "From the data to date, we believe that ofatumumab has real potential. Now that Phase 3 studies are underway in multiple indications, we are moving closer to realizing this potential and bringing this important treatment to patients."

"We are very pleased that our collaboration with Genmab has progressed so that we can now move to the next step of the clinical trial program," said Dr. Moncef Slaoui, Chairman of Research and Development, GlaxoSmithKline. Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of B-cells. This epitope is different than other anti-CD20 a
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
10. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Seven-year-old Riley Salz of Encino, California, is ... 40 hours a week of applied behavior analysis (ABA) ... for Autism and Related Disorders (CARD). Riley has been ... experienced remarkable progress, including learning to speak, starting conversations, ... journey through autism is now featured in CARD’s “Mission ...
(Date:6/18/2013)... Medical Center clinical researchers have launched an innovative ... evaluate the ability of a patient,s own stem ... peripheral arterial disease (PAD). , Led by ... University Hospitals Case Medical Center,s Harrington Heart & ... Western Reserve University School of Medicine, the clinical ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 More than 1.1 ... living with HIV/AIDS, according to the Centers for Disease Control ... they are infected. In support of National HIV Testing Day ... Security Disability Insurance (SSDI) representation, the CDC and other ... , The CDC reports about 50,000 new HIV infections ...
(Date:6/18/2013)... 18, 2013 myCNAjobs announces the addition ... downloads, articles, and tips to the Caregiver Resources Center. ... for the 10,000+ retiring baby boomers each day, the ... caregiver job resources has never been greater. ... community, recently launched the first-ever free resource center ...
(Date:6/18/2013)... A new $119 million industry is taking the ... redefining the way consumers get their seafood. , ... chefs on the Emerald Coast panhandle of Northwest Florida ... the promising industry of aquaculture. , The word “sustainable” ... to fully partake in the effort, especially when it ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2Health News:New $119 Million Industry Swimming Up the East Coast 2
... black woman to be on AMA,s board , MONDAY, July ... he has nominated a rural Alabama family physician to be ... -- the first black woman and youngest doctor ever elected ... her resolve to rebuild her nonprofit medical clinic after it ...
... Leading hearing system ... their work on Hear the World, a global initiative to raise awareness about the importance ... ... the International Stevie Award for Communications Team of the Year for their work on Hear ...
... , , , ... http://www.avacor.com ) has acquired the assets ... Avacor,s FDA approved Physicians, Topical Formulation(R); the All-Natural Nutricap and Boost! ... which allows the company to market and sell the FDA approved ...
... 13, 2009) Twenty hematology and hematology/oncology fellows and ... mentoring program this summer as part of the American ... The ASH Clinical Research Training Institute provides aspiring hematologists ... research. The annual program begins with a week-long summer ...
... 13 CCA Industries, Inc. (NYSE Amex: CAW ), ... 2009 were $14,748,329, net income was $694,136 and earnings per share ... revenue of $17,389,985, net income of $790,692 and fully diluted ... Revenues for the six months ended May 31, 2009 were ...
... , WASHINGTON, July 13 As the health reform ... Future today released the names of prominent health care experts and economists ... insurance option to compete with private plans, but they are good sources ... , "Conservatives and health industry forces are putting ...
Cached Medicine News:Health News:Obama Taps Alabama Doctor to Be Surgeon General 2Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 2Health News:Phonak and Hear the World Wins International Stevie Award in Sixth Annual International Business Awards 3Health News:Avacor(R), Premier Provider of Hair Growth Solutions, Acquired By Investor Group. 2Health News:Promising hematologists begin year-long program to pursue careers in clinical research 2Health News:CCA Industries, Inc. Reports Second Quarter Earnings and Dividend for the Third Quarter. 2Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 2Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 3Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 4Health News:Prominent Health Experts Who Support Public Insurance Option Available for Interview 5
(Date:6/18/2013)... FRANKLIN LAKES, N.J. and NEW YORK ... (Becton, Dickinson and Company) (NYSE: BDX ) are ... insulin infusion and glucose sensing technologies through a new collaboration ... existing JDRF-BD collaborations focused on type 1 diabetes (T1D). ... via an insulin pump – requiring a catheter to be ...
(Date:6/18/2013)... EMERYVILLE, Calif. , June 18, 2013 /PRNewswire/ ... from a Phase 2/3 clinical trial of ADS-5102 ... significant improvement in levodopa-induced dyskinesia (LID) as measured ... placebo in the Unified Dyskinesia Rating Scale (UDysRS). ... intended for once-nightly administration that is being studied ...
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC ... , a technology platform that connects buyers and sellers ... being an industry leader. Why? It,s ... TopProdeals™ are intimately familiar with the dental industry. They ... community and have diligently worked to negotiate some of ...
Breaking Medicine Technology:JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 2JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 2Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 3Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 4Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 5Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease 6TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
... ATLANTA , July 12 Holon, the new ... Medication Management solution. , ... Leveraging the Holon Process Adaptive Interoperability Framework, ... your current medication management solution by automating the collection and ...
... July 12 BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... that its strategic partner Auxilium Pharmaceuticals, Inc. has provided an update ... for the treatment of Dupuytren,s contracture. , ... Auxilium announced that XIAFLEX sales to ...
Cached Medicine Technology:Holon: The Process Adaptive Interoperability Framework 2BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update 2BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
Smooth, contoured visual obturator provides less traumatic insertion through the urethra and into the bladder....
... The URF-P3 features a tip ... minimal invasiveness, an up/down angulation range ... to previously hard-to-reach areas.,For improved observation, ... designed, and a reusable 11.7Fr (3.9mm) ...
... combines efficient stone fragmentation, low purchase price, ... clear LED display, automatic probe sensing circuitry, ... probe size. In addition, the AEH-4 has ... can also regulate and control relative power ...
Medicine Products: